AIKI AIkido Pharma Inc.

AIkido Pharma Inc.

Specialty Chemicals

Consumer Discretionary

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.

IPO Year:

Exchange: NASDAQ

Website: aikidopharma.com

Recent Analyst Ratings for AIkido Pharma Inc.

Date	Price Target	Rating	Analyst
10/11/2021	$2.00	Buy	HC Wainwright & Co.

See more ratings

AIkido Pharma Inc. Press Releases

Fastest customizable press release news feed in the world

Dominari Holdings Provides Update on Share Repurchase Program
NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on December 27, 2022, the Company purchased 4,000 shares of common stock at $3.1012 per share. Anthony Hayes, CEO of Dominari, stated, "The Company's stock is trading at levels we believe are below its intrinsic value. To enhance shareholder value, we are making purchases as part
12/28/22 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)
NEW YORK, Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. The name change was approved at a meeting of the board of directors held on December 5, 2022. Anthony Hayes, CEO of Dominari Holdings Inc., commented, "Rebranding of the C
12/22/22 8:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes
Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. The shares began trading on the Nasdaq Capita
11/28/22 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Share Repurchase Continues
NEW YORK, Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on October 5, 2022, the Company purchased 10,500 shares of common stock at $7.0679 per share. Additional shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Excha
10/6/22 9:10:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Purchases More Shares
NEW YORK, Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share. Anthony Hayes, CEO of AIkido stated, "We believe the Company stock continues to be undervalued and we are using this opportunity to enhance shareholder value by reducing the amount of stock that is
10/5/22 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
Share Repurchase Program Continues
NEW YORK, Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on October 3, 2022, the Company purchased 45,000 shares of common stock at $6.98 per share. Additional shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange A
10/4/22 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Pharma Continues Share Repurchase Program
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on September 30, 2022, the Company purchased 41,096 shares of common stock at $ 7.1034 per share. Anthony Hayes, CEO of Aikido stated, "The Company's stock price is still below our book value, so we are continuing to allocate capital under our repurchase plan. The board believes in the
10/3/22 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Pharma Provides Update on Share Repurchase Program
NEW YORK, Sept. 30, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. In the framework of the Share Repurchase Program, the Company has repurchased 303,886 common shares in the period from January 21, 2022 up to and including September 29, 2022. The price per share range for the shares repurchased was $5.34 to $6.97. Additional shares may be repurchased from time to time in open
9/30/22 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-Dealer
Acquisition Will Accelerate Growth Strategy NEW YORK, Sept. 9, 2022 /PRNewswire/ -- Dominari Financial, Inc., the financial services subsidiary of AIkido Pharma Inc., (NASDAQ:AIKI) has entered into an exclusive agreement for the acquisition of a broker-dealer firm. This is Dominari's first acquisition since launching in June. Details of the proposed purchase can be found in the 8K on file with the SEC. Dominari Financial was formed with the intention of acquiring revenue generating assets in the fintech and financial services industry. "Our goal has always been to move swiftly to execute a roll-up strategy of wealth management firms that cater to ultra-high-net worth investors. This transfor
9/9/22 6:25:00 PM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Pharma Confirms Receipt of Unsolicited Offer
NEW YORK, Aug. 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today confirms that on August 9, 2022, the Company received an unsolicited offer from Mr. Shalom Auerbach to acquire all of the Company's outstanding common stock for $8.00 per share in cash. The Company's Board of Directors will carefully review the proposal to determine the course of action that it believes is in the best interest of the Company and all AIkido shareholders. The Company will respond in due course. There is no need for shareholders to take any action at this
8/10/22 8:30:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary

AIkido Pharma Inc. Leadership Updates

Live Leadership Updates

AIkido Pharma Inc. Appoints New Director, Soo Yu
New Director Supports NASDAQ Rule on Diversity NEW YORK, June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company. Anthony Hayes, CEO of AIkido stated, "At the time of the annual meeting, there was concern expressed by some shareholders about the Company's compliance with the new NASDAQ rules on diversity. The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule. Further, Ms. Yu's background broadens t
6/10/22 4:15:00 PM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching
NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today released the following shareholder update: Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts. To start, we are pleased to announce that last month, DatChat Inc., (NASDAQ:DATS) went public. AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00. As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 ad
9/14/21 9:22:00 AM ET
$AIKI
$DATS
Specialty Chemicals
Consumer Discretionary
Telecommunications Equipment
Telecommunications
AIkido Pharma Provides Business Update
NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. Our research partners continue to make progress towards this focus with positive results in ongoing preclinical studies. In addition, through a series of financing transactions over the course of 2020, and the last several months, we are sufficiently capitalized to support our
4/5/21 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Scott T. Tagawa, M.D., M.S., FACP, a Professor of Medicine and Urology at Weill Cornell Medicine and an Attending Physician at New York-Presbyterian-Weill Cornell Medical Center, has joined the Company's Scientific Advisory Board. "Scott is a leading scholar in the field of oncology medicine and research," commented Mr. Anthony Hayes, CEO of AIkido. "His experience and expertise will be of tremendous value as we further our efforts to develop therapeutic treatments for cancer and leverage the technologies we have licensed. Dr. Tagawa is also the principle investi
2/3/21 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary

AIkido Pharma Inc.

Recent Analyst Ratings for AIkido Pharma Inc.

AIkido Pharma Inc.

Recent Analyst Ratings for AIkido Pharma Inc.

AIkido Pharma Inc. Press Releases

Fastest customizable press release news feed in the world

Dominari Holdings Provides Update on Share Repurchase Program

AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

AIkido Share Repurchase Continues

AIkido Purchases More Shares

Share Repurchase Program Continues

AIkido Pharma Continues Share Repurchase Program

AIkido Pharma Provides Update on Share Repurchase Program

Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-Dealer

AIkido Pharma Confirms Receipt of Unsolicited Offer

AIkido Pharma Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)

Hayes Anthony bought $8,012 worth of shares (4,000 units at $2.00) (SEC Form 4)

Wool Kyle Michael bought $8,122 worth of shares (4,000 units at $2.03) (SEC Form 4)

Devall Christopher Franklin bought $2,278 worth of shares (1,000 units at $2.28), increasing direct ownership by 5% to 23,033 units (SEC Form 4)

Devall Christopher Franklin bought $2,259 worth of shares (1,000 units at $2.26), increasing direct ownership by 5% to 22,033 units (SEC Form 4)

Wool Kyle Michael bought $2,200 worth of shares (1,000 units at $2.20) (SEC Form 4)

Hayes Anthony bought $5,965 worth of shares (2,804 units at $2.13) (SEC Form 4)

Wool Kyle Michael bought $4,103 worth of shares (2,000 units at $2.05) (SEC Form 4)

AIkido Pharma Inc. SEC Filings

AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

SEC Form 10-Q filed by AIkido Pharma Inc.

AIkido Pharma Inc. filed SEC Form 8-K: Other Events

SEC Form 8-A12B filed by AIkido Pharma Inc.

AIkido Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

SEC Form DEFA14A filed by AIkido Pharma Inc.

SEC Form DEF 14A filed by AIkido Pharma Inc.

AIkido Pharma Inc. Financials

Live finance-specific insights

AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

AIkido Pharma Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)

Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)

Hayes Anthony bought $8,012 worth of shares (4,000 units at $2.00) (SEC Form 4)

Wool Kyle Michael bought $8,122 worth of shares (4,000 units at $2.03) (SEC Form 4)

Devall Christopher Franklin bought $2,278 worth of shares (1,000 units at $2.28), increasing direct ownership by 5% to 23,033 units (SEC Form 4)

Devall Christopher Franklin bought $2,259 worth of shares (1,000 units at $2.26), increasing direct ownership by 5% to 22,033 units (SEC Form 4)

Wool Kyle Michael bought $2,200 worth of shares (1,000 units at $2.20) (SEC Form 4)

Hayes Anthony bought $5,965 worth of shares (2,804 units at $2.13) (SEC Form 4)

AIkido Pharma Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. initiated coverage on AIkido Pharma with a new price target

AIkido Pharma Inc. Leadership Updates

Live Leadership Updates

AIkido Pharma Inc. Appoints New Director, Soo Yu

AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching

AIkido Pharma Provides Business Update

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

AIkido Pharma Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by AIkido Pharma Inc.

SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

SEC Form SC 13D filed by AIkido Pharma Inc.

SEC Form SC 13G filed by AIkido Pharma Inc.

SEC Form SC 13G/A filed by AIkido Pharma Inc. (Amendment)

SEC Form SC 13D filed

SEC Form SC 13G filed

SEC Form SC 13G/A filed